Journal
BIO-PROTOCOL
Volume 7, Issue 24, Pages -Publisher
BIO-PROTOCOL
DOI: 10.21769/BioProtoc.2650
Keywords
T cells; T cell homeostasis; Bone marrow chimeras; Busulfan; Temporal fate mapping
Categories
Funding
- National Institutes of Health [R01 AI093870]
- Medical Research Council [MC-PC-13055]
Ask authors/readers for more resources
This protocol was developed to generate chimeric mice in which T lymphocytes could be stratified by age on the basis of congenic marker expression. The conditioning drug busulfan is used to ablate host haematopoietic stem cells while leaving the peripheral immune system intact. Busulfan treatment is followed by bone marrow transplantation (BMT), with T-cell depleted donor bone marrow bearing a different congenic marker (CD45.2) to that of the host mouse (CD45.1). New cell production post-BMT can thus be tracked by measuring the fraction of CD45.2+ cells over time within a population of interest (Hogan et al., 2015; Gossel et al., 2017).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available